Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
1H2027First half of 2027
2Q26Second quarter of 2026
AAAAIAmerican Academy of Allergy, Asthma & Immunology
ACAAIAmerican College of Allergy, Asthma & Immunology
ACEAngiotensin-converting enzyme
ADAAntidrug antibody
ADNAcide désoxyribonucléique (deoxyribonucleic acid)
AEAdverse event
AE-BKBradykinin-mediated angioedema
AE-QoLAngioedema Quality of Life Questionnaire
AECTAngioedema Control Test
Ago2Argonaute 2
AHFSAmerican Hospital Formulary Service
ALTAlanine aminotransferase
AOHAngio-œdème héréditaire (hereditary angioedema)
ARNAcide ribonucléique (ribonucleic acid)
ASOAntisense oligonucleotide
ASPAverage sales price
ASTAspartate aminotransferase
ATEArterial thromboembolism
Big4Big Four (Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard) price
BK2Bradykinin B2
BLABiologics license application
BMIBody mass index
C1-INHC1 esterase inhibitor
C1INHC1 esterase inhibitor
C4Complement component 4
CAPCapsule
CDMOContract development manufacturing organization
CIConfidence interval
CKCreatine phosphokinase
CL/FTotal apparent body clearance
CRISPRClustered regularly interspaced short palindromic repeats
D1Day 1
DFGDébit de filtration glomérulaire (glomerular filtration rate)
DNADeoxyribonucleic acid
EAACIEuropean Academy of Allergy and Clinical Immunology
ECAEnzyme de conversion de l'angiotensine (angiotensin-converting enzyme)
ECGElectrocardiogram
EDEmergency department
eDiaryElectronic diary
ELISAEnzyme-linked immunosorbent assay
EoSEnd of study
EREmergency room
EUEuropean Union
F12Coagulation factor XII gene
FDAFood and Drug Administration
FFPFresh frozen plasma
FSSFederal Supply Schedule
FXIICoagulation factor XII
GalNAcN-acetylgalactosamine
HAHereditary angioedema
HADSHospital Anxiety and Depression Scale
HAEHereditary angioedema
HAE-1Hereditary angioedema type 1 (C1 inhibitor deficiency)
HAE-2Hereditary angioedema type 2 (C1 inhibitor dysfunction)
HAE-C1-INHHereditary angioedema due to C1 inhibitor deficiency
HAE-C1INHHereditary angioedema due to C1 inhibitor deficiency
HAE-FXIIHereditary angioedema associated with a factor XII gene variant
HAE-nC1-INHHereditary angioedema with normal C1 inhibitor
HAE-nC1INHHereditary angioedema with normal C1 inhibitor
HAE-nl-C1INHHereditary angioedema with normal C1 inhibitor
HAE-PLGHereditary angioedema associated with a plasminogen gene variant
HAEAHereditary Angioedema Association
HCPCSHealthcare Common Procedure Coding System
HDI-SFHamilton Depression Inventory-Short Form
HRQoLHealth-related quality of life
HVHealthy volunteer
ICERInstitute for Clinical and Economic Review
INHInhibitor
INJInjection
IRCInsuffisance rénale chronique (chronic kidney disease)
ITTIntent-to-treat
IUInternational units
IVIntravenous
KKKallikrein
KKSKallikrein-kinin system
KLKB1Kallikrein B1 gene
LELaryngeal edema
LINLimite inférieure de la normale (lower limit of normal)
LLOQLower limit of quantification
LTPLong-term prophylaxis
MCIDMinimal clinically important difference
mRNAMessenger RNA
NDANew drug application
NDCNational Drug Code
NHPNonhuman primate
NMANetwork meta-analysis
NOAELNo-observed-adverse-effect level
ODTOn-demand treatment
OLEOpen-label extension
OMIMOnline Mendelian Inheritance in Man
OROdds ratio
ORPHAOrphanet
PBOPlacebo
PDPharmacodynamics
pdC1-INHPlasma-derived C1 inhibitor
pdC1INHPlasma-derived C1 inhibitor
PDUFAPrescription Drug User Fee Act
Ph1Phase 1
PICFParticipant information and consent form
PKPharmacokinetics
PKKPrekallikrein
PKK-KKPrekallikrein-kallikrein
PLGPlasminogen gene
PPPYPer patient per year
PRElectrocardiographic interval from the onset of the P wave to the onset of the QRS complex
Q2WEvery 2 weeks
Q3Third quarter
Q3MEvery 3 months
Q4Fourth quarter
Q4WEvery 4 weeks
Q6MEvery 6 months
Q8WEvery 8 weeks
Q12WEvery 12 weeks
Q24WEvery 24 weeks
QALYQuality-adjusted life-year
QoLQuality of life
QRSElectrocardiographic complex of ventricular depolarization (Q, R, and S waves)
QTElectrocardiographic interval from the onset of the QRS complex to the end of the T wave
QTcFQT interval corrected for heart rate by the Fridericia formula
RECResearch ethics committee
RISCRNA-induced silencing complex
RNARibonucleic acid
RNase H1Ribonuclease H1
RWEReal-world evidence
SADSingle ascending dose
SAESerious adverse event
SCSubcutaneous
SDStandard deviation
SDPSolvent detergent plasma
SECSecurities and Exchange Commission
SEMStandard error of the mean
SERPING1Serpin family G member 1 gene (encodes C1 inhibitor)
SF-1212-Item Short Form Health Survey
siRNASmall interfering RNA
SOLNSolution
SUCRASurface under the cumulative ranking curve
TEAETreatment-emergent adverse event
TSQM-IITreatment Satisfaction Questionnaire for Medication, version II
UKUnited Kingdom
ULNUpper limit of normal
USUnited States
VILVial
VTEVenous thromboembolism
W3Week 3
W5Week 5
W9Week 9
W13Week 13
W17Week 17
W21Week 21
W25Week 25
WACWholesale acquisition cost
WAOWorld Allergy Organization
WHOWorld Health Organization
WPAI-GHWork Productivity and Activity Impairment-General Health questionnaire
XRExtended release
YE2027Year-end 2027